MOHNYSEThe short version
Molina Healthcare, Inc.
Molina Healthcare is a US insurer running government Medicaid, Medicare and ACA health plans for about 5.5 million low-income members across 21 states — here measured against one investor's test for buying deep, fear-driven dislocations.
From a $360.77 peak in September 2024 to a $122.65 trough in February 2026, then an 83% rebound to $224.82 by mid-July 2026.
$225
Share price
$11.9B
Market cap
~8.1%
Normalized adj. FCF yield
−66%
Peak-to-trough drawdown
SwipeScroll▾
The business
A $45B government-health insurer whose earnings just halved
FY2020 → FY2025as reported · $
Revenue$45.4B+12%
Operating margin1.7%−2.5pp
Net income$472M−60%
EPS$8.92−56%
Free cash flow−$636M−$1.2B
As-reported statements, FY2020–FY2025.
- What it is. Molina insures about 5.5 million people on Medicaid, Medicare duals and ACA plans across 21 US states, founded in 1980. It collects a fixed premium per member and profits when the care it arranges costs less.
- The break. FY2025 net income fell to $472M from $1,179M and adjusted EPS to $11.03 from a $24.50 guide, as medical costs outran the rates states pay. Revenue never faltered — it rose to $45.4B.
The fit
Does not fit the framework (P1 not met); contested: P2
Fails
Year-10 durability gate (P1)
~8.1%
Norm. adj. FCF yield vs 8–9% bar
0.37
Probability damage is temporary
High
Confidence in the read
- Why it fails. The gate demands very-high conviction that revenue and cash flow are higher in ten years. Revenue is re-bid on 3–5 year state contracts, and Congress is legislating a 15–20% Medicaid Expansion cut by 2029. The gate is binary; any real doubt fails it.
- The counter-fact. Nothing here says Molina shrinks: revenue more than doubled over the decade to $45.4B with no three-year decline, and the Expansion cut is only about 4–5% of its Medicaid base. It fails on conviction, not on evidence of decline.
What it insures
Three-quarters of premium is Medicaid
FY2025 premium by segment
Medicaid$32.2B75%
Medicare$6.2B14%
Marketplace$4.5B10%
- Medicaid is the core. It is 75% of premium and 83% of members. States pay a fixed per-member rate, and Molina is one of a handful of national plans — Centene, CVS, Elevance, UnitedHealth — bidding for the same contracts.
- Thin by design. Net margin ran about 1% in FY2025, so results turn on the share of each premium dollar spent on care. That ratio rose to 91.7% from 89.1% and roughly halved earnings.
The dislocation
Down 66% in seventeen months, on four guidance cuts
Daily close; peak and trough per the capitulation gauge.
- The fall. From a $360.77 peak the stock bottomed at $122.65 in February 2026, a 66% drop, as full-year 2025 adjusted EPS guidance was cut four times — $24.50 down to an $11.03 actual.
- Capitulation, not drift. Volume spiked to 5.57x its pre-peak median, with a single 10.3M-share session — about 25x normal — on the Q4 loss. Revenue never fell; margin did.
The damage math
At the trough, price fell further than any value case
Damage vs the $360 peak ($/share)
- Two scenarios. A transparent NPV destroys 18% of value if the earnings hit is temporary (about $294 a share) and 52% if permanent (about $171). Both are measured against the $360 pre-event level.
- The gap has closed. At $122.65 the price had destroyed more value than even the harsh permanent case. After an 83% rally to $225 it sits inside the probability-weighted band of about $217–$265.
Temporary or permanent
The trial leans permanent: 0.37 probability temporary
0.37
Probability the damage is temporary
Half
Of the hit is a structural Marketplace exit
60%
Of revenue reprices each January
- Why it leans permanent. A blind three-judge trial put the probability the damage is temporary at 0.37. Roughly half the revision is Molina deliberately pulling $2.3B of Marketplace premium as ACA subsidies lapse — subtraction, not a timing miss.
- What could move it. The Medicaid half has a real repricing mechanism: 60% of revenue resets each January against a cost base about 20% above three years ago. A materially better 2027 rate cycle would tilt the ruling toward temporary.
Yield vs the bar
Normalized yield ~8.1%, short of both bars
Adjusted FCF yield on today's price
Trailing 3-yr avg
1.6%
Through-cycle avg
5.5%
Normalized adjusted
8.1%
Consensus forward (raw)
10.6%
- Single-year yield is unusable. FY2025 free cash flow was negative, so the case rests on normalization. Consensus forward FCF averages about 10.6% of today's cap raw, and about 8.1% after the framework's stock-comp and acquisition haircut.
- Short of both bars. For a net-cash balance sheet the reference line is 8–9%; the default is 10%. At about 8.1% Molina sits at the floor of one and roughly 190 bps under the other — most of that yield lives in a consensus recovery, not trailing cash.
The year-10 gate
A real barrier, owned by the counterparty shrinking the program
Ruchir's conviction sources, graded
| Conviction source | Holds for Molina? |
|---|---|
| Market structure | Partly — revenue re-bid, not owned |
| Regulatory entry barrier | Yes — licensing + $3.1B capital |
| Capital intensity | Partly — regulatory, not physical |
| Essential product | Yes, for the program |
| Long operating history | Yes — 45 years |
- Genuine barriers. State licensing and about $3.1B of statutory capital keep startups out, and Molina has run health plans for 45 years. Two of the five conviction sources clearly hold.
- Where it breaks. Revenue is not owned — it is re-bid every 3–5 years, with four states each over 10% of Medicaid premium. The government both sets the rates and is legislating the program smaller, so very-high conviction is not available.
Self-help
The buyback engine runs, on a thin cash flow
Shares outstanding (millions)
- Executed, not just authorized. Molina spent $1.0B on buybacks in each of 2024 and 2025, cutting the share count 8.3% in a year, and leaned harder as the stock fell — buying at $175 in Q3. $500M of authorization remains.
- The catch. Only $223M of freely-deployable cash sat at the parent; the roughly $8B on the balance sheet is trapped statutory capital. Buybacks rank third behind organic growth and acquisitions for the ~$1.5B annual flow.
The clock
The deepest drawdown ever, and a slow road back
Peak-to-trough drawdowns, 2005–2026 (%)
- Deepest ever. The 66% fall is the largest in Molina's listed history. Its one comparable mature-era drawdown, the 2015–18 ACA scare, took about 29 months to round-trip — a full recovery to old highs is a two-year-plus process.
- The near-term test is now. Management resets full-year guidance with the July 22, 2026 print off a low ≥$5 floor, and the January 2027 Medicaid rate cycle is the real test. The stock already trades above its $211 mean analyst target.
Management
Guidance missed three times, but not the CEO trap
Initial adjusted-EPS guide vs delivered
| Fiscal year | Guided ≥ | Delivered |
|---|---|---|
| FY2023 | $19.75 | $20.88 — beat |
| FY2024 | $23.50 | $22.65 — missed |
| FY2025 | $24.50 | $11.03 — missed |
- The dent. Initial adjusted-EPS guidance missed two years running and then collapsed in 2025, $24.50 to $11.03. Insider ownership is low at 1.44%, so the skin in the game is modest.
- Not disqualifying. The long-tenured CEO delivered his acquisition and buyback promises, bought $2.0B of stock into the fall, and the FY2025 miss is the industry-wide cost-trend error the framework hunts — a repricing event, not promotion.
The re-rating
At $225, the mispricing has largely closed
$225
Price now (Jul 16, 2026)
$217–265
Probability-weighted value band
$123
February trough, far below value
- The gap has closed. At $122.65 the price had fallen below even the harsh permanent case. At $225 it sits inside the $217–$265 probability-weighted band — the market now pays roughly what a permanent-leaning outcome is worth.
- The framework math is unavailable. The profile's re-rating target could not be computed: adjusted FCF is not calculable because stock-based compensation is missing from the feed. What remains is the value band above, and it no longer shows an obvious discount.
What to watch
A genuine, deep dislocation in an essential business that still fails the framework's binary durability gate.
- 01FY2026 adjusted EPS exceeds $10, consolidated MCR falls below 90.5%, and operating cash flow turns above $1 billion
- 02FY2027 Medicaid rates exceed medical cost trend by at least 150 bps and Medicaid pretax margin exceeds 3% with no material retroactive state recoupments
- 03Capital allocation pivots to debt paydown over repurchases
- 04Share count inflects upward
One page distilled from a fixed, tab-by-tab fit test — every number is drawn from the full report.
Compiled from the full report · 2026-07-22 · For information, not investment advice.